The Statin Market Gets Two New Players
Executive Summary
The market for statins, cholesterol-lowering drugs, just got more crowded as Bayer announced a co-promotion with SmithKline, which in turn followed the blockbuster deal for {lipitor} between Pfizer and Warner-Lambert. But some analysts already see a segmentation coming, with Bayer/SB going head-to-head against Bristol-Myer Squibb's {Pravachol}, while {Lipitor} competes against Merck's {Zocor}.